Scientific Insights for Informed Action

Poorly water-soluble active pharmaceutical ingredients continue to present a major formulation challenge due to limited dissolution and inconsistent bioavailability. Soluplus®, an amphiphilic graft copolymer used across multiple dispersion techniques, has been widely investigated for its ability to stabilize amorphous drug forms and enhance solubility.¹

In this recap, we summarize two studies on how solvent-based processing with Soluplus can enable formation of stable amorphous dispersions and support downstream aqueous processing routes that are not achievable through direct aqueous formulation alone.^2,3

Solvent-based SLP/API Mixture for Film Coating Preparation

Direct homogenization of hydrophobic components, including vitamin E, with Soluplus in water does not produce a stable dispersion suitable for film formation, resulting in phase separation and poor processability.² To address this limitation, Salawi et al. dissolved Soluplus and vitamin E were in ethanol and spray dried to form a solid dispersion. This intermediate step enabled subsequent re-dispersion in water, producing stable aqueous systems that maintained homogeneity during processing.²

These aqueous dispersions exhibited droplet sizes on the order of approximately 100 to 350 nanometers and maintained low viscosity at around 0.01 Pa·s despite a 10 percent solids loading, supporting use in spray-based coating applications.²

Films cast from these dispersions were homogeneous and hydrophilic across compositions. Increasing vitamin E con¬centration reduced tensile strength and increased elasticity, with intermediate compositions providing the optimal balance between flexibility and processability.²

When applied in a fluid bed coating process using acetaminophen granules as a model substrate, these materials enabled controlled release behavior. Increasing coating weight gain delayed drug release, with higher coating levels requiring longer time to reach similar dissolution levels compared to uncoated material.²

Solvent-based Casting Method for Ibuprofen

Researchers also evaluated ethanol-based solvent casting to prepare Soluplus dispersions with ibuprofen, a BCS Class II compound with limited aqueous solubility.³

Ibuprofen incorporated into the Soluplus matrix was converted to an amorphous state, as confirmed by the ab¬sence of crystalline peaks in powder X-ray diffraction analysis, indicating molecular-level dispersion within the polymer system.³

This structural change resulted in significantly improved dissolution performance. While pure ibuprofen and physical mixtures showed limited dissolution, Soluplus solid dispersions achieved near-complete dissolution in alkaline media within two hours, with improved performance across additional media conditions.³

Implications

These studies demonstrate that solvent-based processing is a critical enabling step in the formation of functional Soluplus dispersions. Ethanol facilitates uniform drug and polymer interaction, allowing formation of amorphous solid dispersions that cannot be achieved through aqueous processing alone.^2,3

The resulting materials can be reprocessed into aqueous dispersions for coating applications or used directly as films or powders with enhanced dissolution properties. This approach provides a pathway to combine solvent-based dispersion formation with downstream solvent-free manufacturing operations while maintaining control over drug release and bioavailability.^2,3

Key Considerations in Solvent Selection

As solvent based spray drying approaches are used to rapidly screen amorphous dispersion strategies, solvent quality and documentation become increasingly important considerations. Key criteria to consider when selecting a solvent include the following.

• Pharmacopeia, GMP, and Regulatory Alignment: Solvents must be manufactured and handled in line with current Good Manufacturing Practices and meet the requirements of applicable pharmacopeia and governmental standards, e.g., validated analytical methods, documented quality control systems, audit readiness, data transparency with Certificates of Analysis and purity profiles, and demonstrated consistent quality/purity between batches.
• Traceability and Change Control: Manufacturers should be able to trace every solvent delivery to the raw materials, production conditions, and quality control test results. The manufacturer must have formal change notification procedures that enable end-users to assess the impact of any changes on quality control commitments.
• Supply Reliability, Continuity, and Licensing: Reliable supply requires multiple manufacturing sites, strong logistics capabilities, and contingency planning to mitigate disruption across the supply chain.

References

1. Guembe-Michel N, Nguewa P, González-Gaitano G. Soluplus®-Based Pharmaceutical Formulations: Recent Advances in Drug Delivery and Biomedical Applications. International Journal of Molecular Sciences. 2025; 26(4):1499. https://doi.org/10.3390/ ijms26041499.
2. Salawi, A.; Sonju, J. J.; Kamal, M. M.; Abu-Fayyad, A.; Al Hagbani, T.; Nazzal, S. Preparation and Characterization of Aqueous Vitamin E/Soluplus® Dispersions for Film Coating Applications. Drug Dev. Ind. Pharm. 2021, 47 (8), 1335–1341. https://doi.org/10.10 80/03639045.2021.1991367.
3. Salawi, A.; Sonju, J. J.; Nazzal, S.; Abu-Fayyad, A.; Al Hagbani, T.; Kamal, M. M.; Alam, M. S. Pharmaceutical Characterization and Dissolution Behavior of Ibuprofen/Soluplus® Solvent-Cast Films. Trop. J. Pharm. Res. 2023, 22 (2), 227–232. https://doi.org/10.4314/ tjpr.v22i2.1

Soluplus® is a registered trademark of BASF SE.